The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial

MLA

Jianwei Liao, et al. “The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial.” Frontiers in Pharmacology, vol. 13, Mar. 2022. EBSCOhost, https://doi.org/10.3389/fphar.2022.755469.

APA

Jianwei Liao, Liyun Yang, Luping Zhou, Hongbin Zhao, Xiao Qi, Yimin Cui, & Dongsheng Ouyang. (2022). The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.755469

Chicago

Jianwei Liao, Liyun Yang, Luping Zhou, Hongbin Zhao, Xiao Qi, Yimin Cui, and Dongsheng Ouyang. 2022. “The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial.” Frontiers in Pharmacology 13 (March). doi:10.3389/fphar.2022.755469.